Mobia Medical

Executive Summary

Mobia Medical (formerly MicroTransponder) is a private medical device and digital health company pioneering neuromodulation therapies for chronic neurological conditions. Its core platform, Paired Vagus Nerve Stimulation (Paired VNS), combines targeted vagus nerve stimulation with rehabilitative therapy to drive neuroplasticity. The company's first commercial product, the Vivistim System, received FDA approval and is indicated to improve upper limb motor function in chronic stroke survivors. This approval marks a significant milestone, positioning Mobia in the growing neuromodulation market estimated at over $6 billion by 2027. Vivistim is the first FDA-approved therapy that pairs nerve stimulation with rehabilitation, offering a novel approach to stroke recovery where limited treatment options exist. The company is now focused on commercial launch, expanding access through reimbursement, and building clinical evidence for additional indications. Mobia's technology has the potential to address a large unmet need: approximately 7 million stroke survivors in the U.S. suffer from chronic motor deficits. However, as a private company with a single approved product, its valuation and revenue trajectory are uncertain. Key risks include adoption rate, payer coverage, and competition from other neuromodulation and robotics-assisted therapies. The company's success hinges on execution of commercial strategy and expansion of its pipeline into other neurological conditions such as post-stroke aphasia or traumatic brain injury.

Upcoming Catalysts (preview)

• Q4 2027FDA approval or clinical trial data for next indication (e.g., post-stroke aphasia or gait impairment)40% success
• Q2 2027Centers for Medicare & Medicaid Services (CMS) coverage decision or national coverage determination for Vivistim55% success
• Q3 2026Strategic partnership with major rehabilitation hospital network or medical device company for distribution30% success